How do you manage checkpoint inhibitor-associated Vogt-Koyanagi-Harada (VKH) disease in patients who have poorly controlled diabetes?

Management of ocular inflammation secondary to immune checkpoint inhibitors (ICPIs) is a balance between managing ocular disease and not negatively impacting treatment of the underlying malignancy. If there is ICPI-associated VKH disease with serous retinal detachment, use of corticosteroids is unav...